A Prospective, Multicenter Study to Evaluate the JensClip Transcatheter Valve Repair System

NCT05417945 | Unknown

• 1 other identifier: LT-2021-06
• Study Type: interventional
• Target: 124
• Locations: 0 countries
• Sites: N/A

Brief Summary

The clinical trial study is designed as a prospective, multicenter, single-group target value clinical study to evaluate the safety and efficacy of the clinical investigational product and to evaluate its performance using the above clinical trial primary endpoint and secondary endpoint indicators.

Conditions

Degenerative Mitral Valve Disease; Mitral Valve Regurgitation

Outcome Measures

Primary Outcomes (1)

• Clinical success rate at 12 months postoperatively

  Clinical success is defined as no death, no mitral valve-related surgical procedures due to mitral valve incompetence, and no moderate-severe or severe mitral regurgitation (MR \> 2+), with the primary evaluation indicators determined by the Core Laboratory and Clinical Event Committee (CEC).

  12 months

Study Arms (1)

JensClip transcatheter valve repair system

EXPERIMENTAL

Using the JensClip transcatheter valve repair system for the treatment of patients with moderate-severe or severe degenerative mitral regurgitation who are at high surgical risk.

Device: JensClip transcatheter valve repair system

Interventions

JensClip transcatheter valve repair system DEVICE

Transcatheter mitral valve repair system is derived from the "Edge-to-Edge" technique in traditional surgery. The principle is roughly to clamp the midpoint of the anterior leaflet and the midpoint of the posterior leaflet of the mitral valve to form a double-hole inflow channel and then improve the regurgitation.

JensClip transcatheter valve repair system

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥ 18 years;
• Echocardiographically confirmed moderate-severe or severe degenerative mitral regurgitation (regurgitation degree MR ≥ 3+);
• NYHA Classification II-IV.
• LVEF ≥ 20%
• Patients considered at high surgical risk after evaluation by two or more cardiovascular specialists (American Association for Thoracic Surgery STS score: risk of death from mitral valve repair ≥ 6% or from mitral valve replacement ≥ 8% (high risk); or the presence of 2 or more indices of frailty (moderate to severe frailty); or the presence of 2 or more major organ insufficiencies that do not improve postoperatively; or a comprehensive cardiac team assessment that the patient has other combined diseases or factors that make him or her unsuitable for surgery)
• Anatomically suitable for mitral valve repair and assessed as suitable for use of this investigational device.
• Voluntarily participate and sign an informed consent form and be willing to accept relevant examinations and clinical follow-up.

You may not qualify if:

• Severe mitral valve calcification
• Previous implantation of a prosthetic mitral valvuloplasty ring or prosthetic mitral valve, or previous transcatheter mitral valve surgery
• Patients with active infective endocarditis
• Patients with mitral stenosis
• Any intracardiac mass, left ventricular or atrial thrombus detected by echocardiography
• Severe coronary stenosis without surgical or interventional treatment or an acute myocardial infarction within 90 days
• Combined with tricuspid, aortic valve or severe macrovascular pathology requiring surgical or interventional treatment
• Severe pulmonary hypertension (pulmonary artery systolic pressure \> 70 mmHg measured by ultrasound or right heart catheter, if measured at the same time the right heart catheter measurement shall prevail).
• Patients with severe right heart insufficiency
• Hemodynamic instability, defined as systolic blood pressure \<90 mmHg in the absence of afterload-reducing drugs, cardiogenic shock, or use of intra-aortic balloon pump;
• Had a stroke/transient ischemic attack (TIA) within 30 days or severe carotid stenosis (\> 70% stenosis on ultrasonography)
• Have undergone transcatheter cardiovascular intervention (PCI) within 30 days, or cardiovascular surgery within 180 days
• Have had a pacemaker or cardioverter-defibrillator (ICD) implanted, or have undergone cardiac resynchronization therapy (CRT, CRT-D) within 30 days
• Patients with clear coagulation disorders and severe coagulation disorders, or with clear contraindications to the anticoagulant drugs
• Known hypersensitivity to product composition

Sponsors & Collaborators

• Jenscare Scientific: lead

MeSH Terms

Conditions

Mitral Valve Insufficiency

Condition Hierarchy (Ancestors)

Heart Valve Diseases; Heart Diseases; Cardiovascular Diseases

Study Officials

• Shengshou Hu

  FUWAI YUNAN CARDIOVASCULAR HOSPITAL

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Shengshou Hu

CONTACT

18616900716; guyongxin@jenscare.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 6, 2022
• First Posted: June 14, 2022
• Study Start: June 1, 2022
• Primary Completion: May 1, 2024
• Study Completion: December 1, 2024
• Last Updated: June 14, 2022

Record last verified: 2022-06

Data Sharing

• IPD Sharing: Will not share